SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR)
XNCR 13.98-2.7%3:30 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (7)4/7/2014 3:17:55 PM
From: tuck  Read Replies (1) of 136
 
Watching immuno-oncology stocks today in the wake of Juno's/MSKCC's CAR-T trial hold in NHL (due to CRS). At the open, it seemed every stock in the space was getting whipped. But some have recovered, especially Innate. Any reason to believe Innate's trial patients are less at risk for this sort of issue? Especially interesting is BLUE's resilience, since they are specifically a CAR-T player. But perhaps their gene therapy programs are buoying it here (and it's been a bit weak lately, already), as those programs are expected to deliver more near term news.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News